Renaissance Technologies
STRO icon

Renaissance Technologies’s Sutro Biopharma STRO Stock Holding History

Renaissance Technologies’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.44M Sell
97,824
-25,041
-20% -$453K ﹤0.01% 1794
2025
Q4 		$1.42M Sell
122,865
-19,615
-14% -$186K ﹤0.01% 2075
2025
Q3 		$1.24M Buy
142,480
+51,160
+56% +$435K ﹤0.01% 2375
2025
Q2 		$652K Buy
91,320
+4,420
+5% +$36.1K ﹤0.01% 2706
2025
Q1 		$565K Sell
86,900
-14,621
-14% -$230K ﹤0.01% 2693
2024
Q4 		$1.87M Buy
101,521
+18,711
+23% +$571K ﹤0.01% 2101
2024
Q3 		$2.87M Buy
82,810
+10,860
+15% +$426K ﹤0.01% 1786
2024
Q2 		$2.11M Buy
71,950
+23,370
+48% +$924K ﹤0.01% 1855
2024
Q1 		$2.75M Sell
48,580
-17,000
-26% -$751K ﹤0.01% 1815
2023
Q4 		$2.81M Buy
65,580
+35,290
+117% +$1.12M ﹤0.01% 1728
2023
Q3 		$1.05M Buy
30,290
+3,340
+12% +$146K ﹤0.01% 2256
2023
Q2 		$1.25M Buy
26,950
+14,010
+108% +$697K ﹤0.01% 2328
2023
Q1 		$598K Buy
12,940
+9,950
+333% +$631K ﹤0.01% 2787
2022
Q4 		$242K Sell
2,990
-18,600
-86% -$1.29M ﹤0.01% 3328
2022
Q3 		$1.2M Buy
21,590
+6,820
+46% +$404K ﹤0.01% 2386
2022
Q2 		$770K Buy
+14,770
New +$825K ﹤0.01% 2879
2022
Q1 		– Sell
-4,870
Closed -$725K – 4448
2021
Q4 		$725K Buy
+4,870
New +$872K ﹤0.01% 2886
2021
Q1 		– Sell
-3,001
Closed -$652K – 3688
2020
Q4 		$652K Buy
+3,001
New +$497K ﹤0.01% 2710
2020
Q3 		– Sell
-14,951
Closed -$1.16M – 3673
2020
Q2 		$1.16M Buy
+14,951
New +$1.43M ﹤0.01% 2471
2020
Q1 		– Sell
-1,030
Closed -$113K – 3774
2019
Q4 		$113K Buy
+1,030
New +$106K ﹤0.01% 3300

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies's STRO Position: Q1 2026 in Review

Renaissance Technologies reduced its Sutro Biopharma (STRO) stake by 20% in Q1 2026, selling an estimated $453K and leaving 97,824 shares worth $2.44M. The position accounts for ﹤0.01% of the portfolio, ranked #1794.

Renaissance Technologies first reported a position in STRO in Q4 2019 and has held it in 20 quarters since. The position peaked at $2.87M in Q3 2024. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • Renaissance Technologies held 97,824 shares of Sutro Biopharma worth $2.44M as of Q1 2026.
  • Renaissance Technologies sold 25,041 Sutro Biopharma shares in Q1 2026, an estimated $453K.
  • Sutro Biopharma made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #1794 holding.
  • Renaissance Technologies first reported a position in Sutro Biopharma in Q4 2019 and has held it in 20 quarters since.
  • Renaissance Technologies's Sutro Biopharma position peaked at $2.87M in Q3 2024.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.